[go: up one dir, main page]

MX2020011736A - Formulacion de vitamina d de liberacion modificada estabilizada y metodo para administrar la misma. - Google Patents

Formulacion de vitamina d de liberacion modificada estabilizada y metodo para administrar la misma.

Info

Publication number
MX2020011736A
MX2020011736A MX2020011736A MX2020011736A MX2020011736A MX 2020011736 A MX2020011736 A MX 2020011736A MX 2020011736 A MX2020011736 A MX 2020011736A MX 2020011736 A MX2020011736 A MX 2020011736A MX 2020011736 A MX2020011736 A MX 2020011736A
Authority
MX
Mexico
Prior art keywords
formulation
administring
same
modified release
stabilized
Prior art date
Application number
MX2020011736A
Other languages
English (en)
Inventor
Jay A White
Joel Z Melnick
Sammy A Agudoawu
Samir P Tabash
Original Assignee
Opko Ireland Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50478969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020011736(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Ireland Global Holdings Ltd filed Critical Opko Ireland Global Holdings Ltd
Publication of MX2020011736A publication Critical patent/MX2020011736A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)

Abstract

Se describe una formulación estabilizada para liberación controlada de un compuesto de vitamina D. La formulación consta de una o ambas de 25-hidroxivitamina D2 y 25-hidroxivitamina D3 y un compuesto celulósico. Las formulaciones estabilizadas exhiben un perfil de disolución estable que sigue la exposición a condiciones de almacenamiento y demuestran parámetros farmacocinéticos mejorados comparados con formulaciones no estabilizadas.
MX2020011736A 2013-03-15 2015-09-11 Formulacion de vitamina d de liberacion modificada estabilizada y metodo para administrar la misma. MX2020011736A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361801896P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
MX2020011736A true MX2020011736A (es) 2021-01-08

Family

ID=50478969

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012625A MX2015012625A (es) 2013-03-15 2014-03-14 Formulacion de vitamina d de liberacion modificada estabilizada y metodo para administrativa y metodo para administrar la misma.
MX2020011736A MX2020011736A (es) 2013-03-15 2015-09-11 Formulacion de vitamina d de liberacion modificada estabilizada y metodo para administrar la misma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012625A MX2015012625A (es) 2013-03-15 2014-03-14 Formulacion de vitamina d de liberacion modificada estabilizada y metodo para administrativa y metodo para administrar la misma.

Country Status (37)

Country Link
US (7) US9861644B2 (es)
EP (4) EP2968172B8 (es)
JP (4) JP6492051B2 (es)
KR (4) KR101847947B1 (es)
CN (2) CN111346071B (es)
AR (1) AR095576A1 (es)
AU (2) AU2014228069B2 (es)
BR (1) BR112015023658A2 (es)
CA (1) CA2905409C (es)
CL (1) CL2015002659A1 (es)
CR (1) CR20190178A (es)
CY (3) CY1123167T1 (es)
DE (1) DE202014011525U1 (es)
DK (3) DK3650016T3 (es)
EA (2) EA201991774A1 (es)
EC (1) ECSP23024864A (es)
ES (3) ES2882567T3 (es)
HK (1) HK1220128A1 (es)
HR (3) HRP20201284T1 (es)
HU (3) HUE051923T2 (es)
IL (2) IL241456B (es)
LT (3) LT3332773T (es)
MX (2) MX2015012625A (es)
MY (2) MY194092A (es)
NO (1) NO2021007I1 (es)
PE (1) PE20151761A1 (es)
PH (2) PH12015502162A1 (es)
PL (3) PL3650016T3 (es)
PT (3) PT3332773T (es)
RS (3) RS62176B1 (es)
SA (1) SA515361134B1 (es)
SG (2) SG11201507323PA (es)
SI (3) SI2968172T1 (es)
SM (3) SMT202000651T1 (es)
TW (1) TWI659753B (es)
UA (1) UA123386C2 (es)
WO (1) WO2014143941A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426391B2 (en) 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
SI2679228T1 (en) 2006-06-21 2018-06-29 Opko Ireland Global Holdings, Ltd. THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
RS60087B1 (sr) 2010-03-29 2020-05-29 Opko Ireland Global Holdings Ltd Postupci i kompozicije za snižavanje nivoa paratireoidnog hormona
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
JP2017523220A (ja) * 2014-08-07 2017-08-17 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3053598A1 (en) 2015-02-06 2016-08-10 Faes Farma, S.A. Calcifediol soft capsules
JP7034595B2 (ja) * 2016-03-23 2022-03-14 株式会社ファンケル ビタミンｄ３安定化組成物
SG11201808227YA (en) 2016-03-28 2018-10-30 Opko Ireland Global Holdings Limited Methods of vitamin d treatment
CA3072427C (en) 2017-08-08 2023-12-05 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
KR20200140284A (ko) 2018-04-03 2020-12-15 옵코 아일랜드 글로벌 홀딩스 리미티드 비만대사 수술 환자에서의 칼시페디올의 용도
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
CN108902985A (zh) * 2018-06-08 2018-11-30 唐飞 25-羟基维生素d3在制备保健食品中的应用
TWI856972B (zh) * 2018-08-31 2024-10-01 愛爾蘭商歐科愛爾蘭全球控股股份有限公司 兒童劑型、製造及使用方法
KR102715550B1 (ko) * 2018-12-10 2024-10-10 신성대학교 산학협력단 유효성분을 함유하는 왁스 파티클 및 이의 제조방법
CN109632444A (zh) * 2018-12-24 2019-04-16 郑州安图生物工程股份有限公司 液态25-羟基维生素d校准品稀释液
EP3920938A1 (en) 2019-02-06 2021-12-15 EirGen Pharma Ltd. Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
CN110917169A (zh) * 2019-12-11 2020-03-27 正大制药（青岛）有限公司 帕立骨化醇胶囊剂及其制备方法
CN115023225A (zh) 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物
JP2023520591A (ja) 2020-04-06 2023-05-17 エアジェン ファーマ リミテッド Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ
WO2021245458A1 (en) 2020-05-31 2021-12-09 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof
CN111991404B (zh) * 2020-10-10 2021-08-13 西南医科大学 防治真菌感染的复合维生素d及其应用
IT202100015845A1 (it) 2021-06-17 2022-12-17 I B N Savio S R L Processo di formulazione della vitamina d / vitamin d formulation process
CN115266992A (zh) * 2022-08-02 2022-11-01 人福普克药业（武汉）有限公司 一种测定维生素d类软胶囊溶出的方法
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565924A (en) 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3833622A (en) 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
GB1405088A (en) 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US3880894A (en) 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS55139320A (en) 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
JPS57188520A (en) 1981-05-15 1982-11-19 Kureha Chem Ind Co Ltd Antihyperkalemia
US4442093A (en) 1981-05-15 1984-04-10 Kureha Kagaku Kogyo Kabushiki Kaisha Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia
JPS5832823A (ja) 1981-08-20 1983-02-25 Chugai Pharmaceut Co Ltd 脱癌剤
JPS58206524A (ja) 1982-05-26 1983-12-01 Kureha Chem Ind Co Ltd 抗腫瘍剤
US4448721A (en) 1982-09-20 1984-05-15 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 compounds and process for preparing same
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja) 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4795327A (en) 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
EP0207638B1 (en) 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
JPS61293911A (ja) 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US4795642A (en) 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US5167965A (en) 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
US4892821A (en) 1987-07-08 1990-01-09 Taisho Pharmaceutical Co., Ltd. Method for preparing vitamin D compounds
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JP2525478B2 (ja) 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
JPH02240024A (ja) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JPH04198129A (ja) 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
JP2893140B2 (ja) 1990-11-30 1999-05-17 エスエス製薬株式会社 安定なビタミンｄ製剤
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
IE75709B1 (en) * 1991-04-09 1997-09-10 Takeda Chemical Industries Ltd Stabilised vitamin D preparation
US5693615A (en) 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
CA2116238C (en) 1992-06-22 2007-09-04 Joyce C. Knutson Oral 1 .alpha.-hydroxyprevitamin d
US5354743A (en) 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en) 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US6121469A (en) 1993-12-23 2000-09-19 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (ja) 1994-03-02 1995-09-19 Teijin Ltd 二次性副甲状腺機能亢進症治療剤
IL110117A0 (en) * 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
EP0769936A1 (en) 1994-07-22 1997-05-02 G.D. Searle & Co. Self-emulsifying drug delivery system
JPH0892098A (ja) 1994-09-27 1996-04-09 Teijin Ltd 肺結核治療剤
UA55374C2 (uk) 1994-10-21 2003-04-15 Нпс Фармасьютікалз, Інк Сполуки, що мають активність по відношенню до рецепторів кальцію
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US20020183288A1 (en) 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
AU717238B2 (en) 1995-09-21 2000-03-23 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
DE19536387A1 (de) 1995-09-29 1997-04-03 Basf Ag Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
US5939408A (en) 1996-05-23 1999-08-17 Hoffman-La Roche Inc. Vitamin D3 analogs
NO971934L (no) 1996-05-23 1997-11-24 Hoffmann La Roche Flourinerte vitamin D3 -analoger
ID18079A (id) 1996-08-26 1998-02-26 Takeda Chemical Industries Ltd Komposisi farmasi yang mengandung bahan pemercepat osteogenesis
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
US5976784A (en) 1996-09-20 1999-11-02 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
EP0935523B1 (en) 1996-10-28 2004-09-29 Inc. General Mills Embedding and encapsulation of controlled release particles
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
JPH10158171A (ja) 1996-12-02 1998-06-16 Kita:Kk ビタミンｄ化合物を配合した眼内投与剤
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6034075A (en) 1997-03-20 2000-03-07 The Trustees Of Columbia University In The City Of New York Method of treating polycystic ovarian syndrome
US5872113A (en) 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
DK1009387T3 (da) 1997-07-02 2006-08-14 Euro Celtique Sa Stabiliserede tramadolformuleringer med langvarig frigivelse
JPH1175863A (ja) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd ２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ
US6096876A (en) 1997-08-06 2000-08-01 Shriners Hospitals For Children 1-α-hydroxylase materials and methods
US20020076442A1 (en) 1997-09-02 2002-06-20 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US5919986A (en) 1997-10-17 1999-07-06 Hoffmann-La Roche Inc. D-homo vitamin D3 derivatives
JPH11158074A (ja) 1997-12-03 1999-06-15 Hayashi Tomie 高アミノ酸付加活性型ビタミンｄ強化組成物
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
CN1301298A (zh) 1998-03-25 2001-06-27 卡坦诺根公司 用于预防和治疗癌症的方法
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US8133694B2 (en) 1998-06-25 2012-03-13 Immundiagnostik Ag Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
WO2000006126A1 (en) 1998-07-28 2000-02-10 Takeda Chemical Industries, Ltd. Rapidly disintegrable solid preparation
US6214376B1 (en) 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
US6770295B1 (en) 1998-08-27 2004-08-03 Pharmacia Ab Therapeutic formulation for administering tolterodine with controlled release
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
DK1119345T3 (da) 1998-10-09 2009-08-03 Gen Mills Inc Indkapsling af fölsomme flydende bestanddele i en matrix til opnåelse af adskilte opbevaringsstabile partikler
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
JP2000206312A (ja) 1998-11-12 2000-07-28 Olympus Optical Co Ltd 光学素子
JP2002532406A (ja) 1998-12-17 2002-10-02 アルザ・コーポレーション 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60031666T2 (de) 1999-04-01 2007-08-30 The Johns Hopkins University NICHT-CALCEMISCHE, TRANSKRIPTIONELL-AKTIVE, SCHWEFELHALTIGE ANALOGA VON 1-alpha, 25-DIHYDROXYVITAMIN D3 MIT ANTIPROLIFERATIVER WIRKUNG
US7648826B1 (en) 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
AU5139600A (en) 1999-05-27 2000-12-18 Drugtech Corporation Nutritional formulations
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
HK1047054B (zh) 1999-08-31 2005-04-15 Chugai Seiyaku Kabushiki Kaisha 软胶囊剂
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
CA2414407A1 (en) 2000-07-18 2002-01-24 Bone Care International, Inc. Stabilized 1.alpha.-hydroxy vitamin d
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
EP1323404B1 (en) 2000-08-29 2013-10-16 Nisshin Kasei Co.,Ltd. Hard capsule
US6887493B2 (en) * 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
US6479649B1 (en) 2000-12-13 2002-11-12 Fmc Corporation Production of carrageenan and carrageenan products
JP2002302447A (ja) 2001-04-03 2002-10-18 Shimizu Pharmaceutical Co Ltd 局所投与用癌治療剤
EP1392246A1 (en) 2001-05-15 2004-03-03 Warner-Lambert Company LLC Compaction process for manufacture of sodium phenytoin dosage form
EP1410794A1 (en) 2001-07-05 2004-04-21 Wakunaga Pharmaceutical Co., Ltd. Soft capsules
CA2454200A1 (en) 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US6870833B2 (en) 2001-07-20 2005-03-22 Net2Phone, Inc. Active voice messaging
US7166585B2 (en) 2001-08-22 2007-01-23 Cytochroma Inc. 24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
US7033996B2 (en) 2001-08-31 2006-04-25 University Of Medicine & Dentistry Of New Jersey Method for the treatment of vitamin D related disease
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP4436674B2 (ja) 2001-10-12 2010-03-24 ジョンズ ホプキンス ユニバーシティ １α，２５−ジヒドロキシビタミンＤ３の低カルシウム血症性オキシム類似体
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
KR20100047349A (ko) 2001-11-22 2010-05-07 모리시타 진탄 가부시키가이샤 비젤라틴계 캡슐 피막 조성물 및 이를 이용한 캡슐
GB0128415D0 (en) 2001-11-27 2002-01-16 Univ Sheffield Medicaments
CN100391464C (zh) 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
FR2829142B1 (fr) 2001-12-27 2004-02-13 Ulice Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NO20021592D0 (no) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
US20030190355A1 (en) 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
CA2480814A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
CA2481486C (en) 2002-04-10 2012-06-12 Fred H. Miller Multi-phase, multi-compartment capsular system
WO2003093459A1 (en) 2002-05-02 2003-11-13 Cytochroma Inc. Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof
AU2003233735A1 (en) 2002-06-13 2003-12-31 Cytochroma Inc. 24-sulfoximine vitamin d3 compounds
RU2336865C2 (ru) 2002-07-05 2008-10-27 Темрел Лимитед Композиция с контролируемым высвобождением
MY142179A (en) 2002-07-25 2010-10-15 Glaxo Group Ltd Multicomponent pharmaceutical dosage form
CN1684670A (zh) 2002-07-29 2005-10-19 阿尔扎公司 用于控制释放帕潘立酮的方法和剂型
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
AU2002368245A1 (en) 2002-09-26 2004-04-19 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (ja) 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
DE10393906T5 (de) 2002-12-16 2006-01-12 Teva Pharmaceutical Industries Ltd. Verfahren zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin D-Derivats
DE20321698U1 (de) 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
CA2510228C (en) 2002-12-18 2012-10-30 Johns Hopkins University 25-so2-substituted analogs of 1.alpha.,25-dihydroxyvitamin d3
EP1592410B1 (en) 2003-02-11 2008-07-23 Alza Corporation Methods and dosage forms with modified layer geometry
US7816341B2 (en) 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
MXPA05011028A (es) 2003-04-14 2005-12-12 Fmc Corp Sistemas de suministro de pelicula de gel termo-reversible homogenea que contiene carragenano kappa-2.
WO2004098507A2 (en) 2003-04-30 2004-11-18 Bioxell S.P.A. 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
AU2004237437B2 (en) * 2003-05-07 2011-01-20 Osteologix A/S Controlled release composition containing a strontium salt
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1638508B1 (en) 2003-06-16 2014-08-13 Solx, Inc. Shunt for the treatment of glaucoma
ATE536861T1 (de) 2003-06-26 2011-12-15 Control Delivery Sys Inc Bioerodierbare arzneimittelabgabesysteme mit verzögerter freisetzung
KR101435167B1 (ko) 2003-06-27 2014-11-04 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
AU2003903382A0 (en) 2003-07-03 2003-07-17 Medvet Science Pty Ltd Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof
KR20060105735A (ko) 2003-07-04 2006-10-11 니코메드 덴마크 에이피에스 경구용 부갑상선 호르몬 함유 약학 조성물
US20050148557A1 (en) 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
PT2821067T (pt) 2003-09-12 2017-12-01 Amgen Inc Formulação de cinacalcet de dissolução rápida
EP1694333A2 (en) 2003-11-25 2006-08-30 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
EP1715847A1 (en) 2003-12-23 2006-11-02 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a hiv protease inhibitor6
KR20060130723A (ko) 2004-03-10 2006-12-19 쉐링 악티엔게젤샤프트 분자 분산된 드로스피레논을 포함하는 조성물
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
EP1765385A4 (en) 2004-06-16 2008-08-27 Smart Drug Systems Inc IMPORTS COMPOSITION WITH DELAYED RELEASE
WO2006007323A2 (en) 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en) 2004-07-22 2006-01-26 David Boardman Process for preparing stabilized vitamin D
AU2005266459A1 (en) 2004-07-29 2006-02-02 Sanofi-Aventis Pharmaceutical multilayer tablet for controlled release of active ingredients with highly pH-dependent solubility
WO2006018119A1 (en) 2004-08-19 2006-02-23 Dsm Ip Assets B.V. Novel compositions of fat-soluble substances
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
US7067568B1 (en) 2004-12-03 2006-06-27 Council Of Scientific And Industrial Research Process of preparation of biodegradable films from semi refined kappa carrageenan
IL166114A0 (en) 2005-01-03 2006-01-15 Calcident Active Ltd Long-acting controlled-release pharmaceutical preparation for use in the oral cavity
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
DE102005011029A1 (de) 2005-03-08 2006-09-14 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die perorale Applikation mit gesteuerter Freisetzung von Wirkstoffen
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
EP1871384A4 (en) 2005-04-15 2012-01-25 Clarus Therapeutics Inc SYSTEMS FOR THE PHARMACEUTICAL ADMINISTRATION OF HYDROPHOUS ACTIVE SUBSTANCES AND COMPOSITIONS THEREWITH
US20060257481A1 (en) 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US20080134937A1 (en) 2005-05-25 2008-06-12 Joo Hwan Yang Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (es) 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
US7895596B2 (en) 2005-09-13 2011-02-22 Hewlett-Packard Development Company, L.P. Processor assignment in multi-processor systems
CA2624124A1 (en) 2005-09-29 2007-04-12 F. Hoffmann-La Roche Ag Antibodies against 25-hydroxyvitamin d
ITFI20050206A1 (it) 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
CA2624897C (en) 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
EP1951208A2 (en) 2005-10-26 2008-08-06 Banner Pharmacaps Inc. Lipophilic vehicle-based dual controlled release matrix system as capsule fill
WO2007050975A2 (en) 2005-10-26 2007-05-03 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
EP1954250A2 (en) 2005-11-01 2008-08-13 Andries Hanzen Films and capsules made from modified carboxymethycellulose materials and methods of making same
WO2007068287A1 (en) 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
MXPA05014091A (es) 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus
US20070207488A1 (en) 2006-01-31 2007-09-06 Trump Donald L Method for identifying altered vitamin D metabolism
US7528122B2 (en) 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US8426391B2 (en) 2006-02-03 2013-04-23 Proventiv Therapeutics, Llc Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
GB0606426D0 (en) 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
CL2007001628A1 (es) 2006-06-06 2008-01-11 Fmc Corp Composicion quimica que comprende i) kappa-2-carragenano, ii) un minimo de 70% de sodio en peso de todos los cationes en esa composicion y iii) entre 0-25% de una sal libre, con una viscosidad de 20 a 40 cps; forma solida; pelicula de gel homogenea, temorreversible; composicion de recubrimiento.
US20080109983A1 (en) 2006-11-10 2008-05-15 Kegel, Llc Zero Turning Radius Lane Maintenance Machine
SI2679228T1 (en) 2006-06-21 2018-06-29 Opko Ireland Global Holdings, Ltd. THERAPY WITH THE USE OF VITAMIN D ADDITIONAL FIBER AND HORMON RESISTANCE OF VITAMIN D
US7387328B2 (en) 2006-09-07 2008-06-17 Willey Barry A Cycle windshield
EP1912400A1 (en) 2006-10-10 2008-04-16 Matsushita Electric Industrial Co., Ltd. Method and apparatus for mobile IP route optimization
US20100168410A1 (en) 2006-10-27 2010-07-01 Pfizer Products Inc. Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture
EP2561877A1 (en) 2006-12-20 2013-02-27 Mylan Pharmaceuticals ULC A Composition containing a Bisphosphonic Acid in combination with Vitamin D
US8501717B2 (en) 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
US8491937B2 (en) 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements
WO2008116113A1 (en) 2007-03-20 2008-09-25 Electrolock, Inc. Roebel winding with conductive felt
US20100144679A1 (en) 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
US8592401B2 (en) 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
US20090004284A1 (en) 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
CN201113125Y (zh) * 2007-07-10 2008-09-10 富士康(昆山)电脑接插件有限公司 电池连接器
KR100836960B1 (ko) 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
EP2042165A1 (de) 2007-09-28 2009-04-01 Swiss Caps Rechte und Lizenzen AG Hot-Melt-Befüllte Weichkapseln
US20090104206A1 (en) 2007-10-19 2009-04-23 Mark Zamoyski Bone microenvironment modulated migraine treatments
AU2007362356A1 (en) 2007-12-12 2009-06-18 Northern Innovations And Formulations Corp. Particles in a capsule
WO2009101132A1 (en) 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Combination of vitamin d and 25-hydroxyvitamin d 3
BRPI0907954A2 (pt) 2008-02-13 2015-08-04 Dsm Ip Assets Bv Tratamento de hipertensão com 25-hidroxivitamina d3
MX2010008904A (es) 2008-02-13 2010-11-05 Dsm Ip Assets Bv Uso de 25-hidroxi-vitamina d3 para afectar la fisiologia muscular humana.
KR20100126376A (ko) 2008-02-13 2010-12-01 디에스엠 아이피 어셋츠 비.브이. 골 무기질 밀도를 개선시키고 골다공증을 치료하기 위한 25-하이드록시-비타민 ｄ3과 비타민 ｄ3의 조합된 용도
JP5691072B2 (ja) 2008-02-13 2015-04-01 ディーエスエム アイピー アセッツ ビー．ブイ． ２５−ヒドロキシビタミンｄ３を用いた高血糖の治療
CA2714996C (en) 2008-04-02 2020-04-07 Cytochroma Inc. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
CA2721269A1 (en) 2008-04-15 2009-10-22 Osteogenex Inc. Compounds and methods for altering bone growth
US8324191B2 (en) 2008-07-11 2012-12-04 Biolink Life Sciences, Inc Combined calcium, magnesium and vitamin D supplements
JP6095891B2 (ja) 2008-07-24 2017-03-15 ウイスコンシン アラムナイ リサーチ ファウンデーシヨンＷｉｓｃｏｎｓｉｎ Ａｌｕｍｎｉ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ２５−ヒドロキシビタミンｄ３を含む経口剤形、及び、その経口剤形を週１回ヒトに投与することを含む方法
SI2341899T1 (sl) 2008-09-24 2015-04-30 Evonik Roehm Gmbh Od pH odvisen opioidni farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola
ES2425762T3 (es) 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
CN102271664B (zh) 2009-01-23 2013-11-20 方济各安吉利克化学联合股份有限公司 控释药物或食品制剂及其制备方法
CH700543A2 (de) 2009-03-03 2010-09-15 Innogel Ag Film auf Basis von Stärke.
KR101760534B1 (ko) 2009-09-10 2017-07-21 에프엠씨 코포레이션 이음매 없는 알기네이트 캡슐
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
US20120301513A1 (en) 2009-10-20 2012-11-29 Herbonis Ag Composition comprising solanum glaucophyllum for preventing and/or treating hypocalcaemia and for stabilizing blood calcium levels
IT1396937B1 (it) 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
US8101203B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
US8101204B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
RS60087B1 (sr) 2010-03-29 2020-05-29 Opko Ireland Global Holdings Ltd Postupci i kompozicije za snižavanje nivoa paratireoidnog hormona
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
KR20120005228A (ko) 2010-07-08 2012-01-16 주식회사 네비팜 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법
BR112013002721B8 (pt) 2010-08-04 2021-05-25 Scherer Technologies Llc R P composição formadora de filme para cápsulas moles, cápsulas moles e seu invólucro
US20130263297A1 (en) 2010-11-10 2013-10-03 Cedars-Sinai Medical Center Methods of treating cancer
US20120135103A1 (en) 2010-11-30 2012-05-31 Mead Johnson Nutrition Company Staged Infant Feeding Regimen To Promote Healthy Development And Growth
WO2012076429A1 (en) 2010-12-06 2012-06-14 Dsm Ip Assets B.V. Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3
RU2579312C2 (ru) 2010-12-28 2016-04-10 Футуре Диагностикс Б.В. Реагент для высвобождения витамина d
ES2641091T3 (es) 2011-03-02 2017-11-07 D3 Pharma Limited Composición de vitamina D
CA2833633A1 (en) 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response
ES2617654T3 (es) 2011-04-20 2017-06-19 Suheung Co., Ltd. Composición de la cubierta de cápsula blanda de origen no animal que tiene dureza de la cubierta y desintegración, mejoradas
CN102771688A (zh) 2011-05-13 2012-11-14 富曼实（上海）商贸有限公司 可食用液体填充的多糖胶囊
WO2012163836A1 (en) 2011-05-27 2012-12-06 Dsm Ip Assets B.V. Extrusion process
US20130085121A1 (en) 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
US9877929B2 (en) * 2011-10-13 2018-01-30 Premier Dental Products Company Topical vitamin D and ubiquinol oral supplement compositions
WO2014029953A1 (en) 2012-08-21 2014-02-27 Cipla Limited Hot melt extruded (hme) pharmaceutical composition of cinacalcet
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
PT106978A (pt) 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d
EP2815745A1 (en) 2013-06-21 2014-12-24 Swiss Caps Rechte und Lizenzen AG Soft shell capsule and process for its manufacture
CN103495176B (zh) 2013-10-26 2015-01-28 中山市凯博思淀粉材料科技有限公司 一种共混挤出法制备淀粉基软胶囊的方法
CN103520133B (zh) 2013-10-26 2015-02-04 中山市凯博思淀粉材料科技有限公司 一种淀粉基软胶囊的制备方法
TWI645864B (zh) * 2014-03-14 2019-01-01 歐科二代智財控股公司 經穩定之修飾釋放維他命ｄ調配物及其服用方法
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP2017523220A (ja) 2014-08-07 2017-08-17 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法
US10998308B2 (en) 2019-07-22 2021-05-04 Texas Instruments Incorporated Area-efficient bi-directional ESD structure

Also Published As

Publication number Publication date
SG10201703517VA (en) 2017-06-29
KR20190095216A (ko) 2019-08-14
EP3332773B1 (en) 2020-08-26
EA201591809A1 (ru) 2016-02-29
RS60846B1 (sr) 2020-10-30
AU2019200268A1 (en) 2019-02-07
UA123386C2 (uk) 2021-03-31
SMT202100439T1 (it) 2021-11-12
CN105246464A (zh) 2016-01-13
LT2968172T (lt) 2020-10-26
LT3650016T (lt) 2021-09-27
RS61132B1 (sr) 2020-12-31
KR20210078463A (ko) 2021-06-28
SI3650016T1 (sl) 2022-04-29
HUE052014T2 (hu) 2021-04-28
DK2968172T3 (da) 2020-09-14
NO2021007I1 (no) 2021-02-19
AU2014228069B2 (en) 2019-01-31
IL241456B (en) 2020-06-30
IL274841A (en) 2020-07-30
BR112015023658A2 (pt) 2017-07-18
CY1123568T1 (el) 2022-03-24
HRP20211265T1 (hr) 2021-11-12
TWI659753B (zh) 2019-05-21
EP3332773A1 (en) 2018-06-13
SMT202000424T1 (it) 2020-09-10
US20260034148A1 (en) 2026-02-05
EP3650016A1 (en) 2020-05-13
DE202014011525U1 (de) 2021-11-11
PL2968172T3 (pl) 2020-12-28
NZ711924A (en) 2021-01-29
CY1123167T1 (el) 2021-10-29
HUE051923T2 (hu) 2021-03-29
US10357502B2 (en) 2019-07-23
US10350224B2 (en) 2019-07-16
HRP20201284T1 (hr) 2020-12-11
HK1220128A1 (zh) 2017-04-28
MY194092A (en) 2022-11-11
AR095576A1 (es) 2015-10-28
AU2014228069A1 (en) 2015-10-01
JP2018012737A (ja) 2018-01-25
ES2809477T3 (es) 2021-03-04
JP6533268B2 (ja) 2019-06-19
ES2882567T3 (es) 2021-12-02
CY1124393T1 (el) 2022-07-22
EP2968172B8 (en) 2020-10-07
EP3888638A1 (en) 2021-10-06
PT3332773T (pt) 2020-11-24
KR20140140004A (ko) 2014-12-08
AU2019200268B2 (en) 2021-04-01
CA2905409C (en) 2023-01-03
CR20190178A (es) 2019-09-02
US20180271885A1 (en) 2018-09-27
LT3332773T (lt) 2020-12-10
KR20140113374A (ko) 2014-09-24
PT2968172T (pt) 2020-08-27
MY200794A (en) 2024-01-16
PH12015502162A1 (en) 2016-01-25
EP2968172A1 (en) 2016-01-20
SA515361134B1 (ar) 2017-10-16
WO2014143941A1 (en) 2014-09-18
SG11201507323PA (en) 2015-10-29
KR101847947B1 (ko) 2018-05-28
US20190374555A1 (en) 2019-12-12
JP2019135264A (ja) 2019-08-15
KR102203003B1 (ko) 2021-01-13
US20220125806A1 (en) 2022-04-28
US20180117068A1 (en) 2018-05-03
SI2968172T1 (sl) 2020-12-31
PL3332773T3 (pl) 2021-03-08
JP2021155460A (ja) 2021-10-07
HK1256895A1 (en) 2019-10-04
US20180271884A1 (en) 2018-09-27
IL241456A0 (en) 2015-11-30
US10300078B2 (en) 2019-05-28
TW201707689A (zh) 2017-03-01
PE20151761A1 (es) 2015-12-16
US12478631B2 (en) 2025-11-25
ES2834900T3 (es) 2021-06-21
SI3332773T1 (sl) 2021-03-31
US11253528B2 (en) 2022-02-22
US20140349979A1 (en) 2014-11-27
CN111346071B (zh) 2025-12-19
JP6492051B2 (ja) 2019-03-27
EP2968172B1 (en) 2020-07-22
EP3650016B1 (en) 2021-05-05
SMT202000651T1 (it) 2021-01-05
US9861644B2 (en) 2018-01-09
HRP20201869T1 (hr) 2021-04-02
DK3650016T3 (da) 2021-08-09
CA2905409A1 (en) 2014-09-18
CN111346071A (zh) 2020-06-30
PH12021551127A1 (en) 2021-12-13
CL2015002659A1 (es) 2016-04-15
JP2016517429A (ja) 2016-06-16
EA038867B1 (ru) 2021-10-29
JP7282832B2 (ja) 2023-05-29
MX2015012625A (es) 2016-07-06
PT3650016T (pt) 2021-07-28
EP3332773B8 (en) 2020-10-14
DK3332773T3 (da) 2020-11-30
HUE055591T2 (hu) 2021-12-28
EA201991774A1 (ru) 2019-11-29
HK1220362A1 (zh) 2017-05-05
ECSP23024864A (es) 2023-05-31
RS62176B1 (sr) 2021-08-31
PL3650016T3 (pl) 2021-12-27

Similar Documents

Publication Publication Date Title
ECSP23024864A (es) Formulación de vitamina d de liberación modificada y estabilizada y método de administración de la misma
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CO7091182A2 (es) Inhibidores de beta-lactamasa isoxazol
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
CL2016000925A1 (es) Inhibidores de bromodominio
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
CL2015002473A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhibidores de la phd.
MX2018003357A (es) Proceso de compuesto antifungico.
MX382747B (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
CL2014002880A1 (es) Compuestos derivados de heterociclos nitrogenados o sus sales, inhibidores selectivos de la pde2a; medicamento que los comprende; y su uso para la profilaxis y tratamiento de la esquizofrenia.
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
UY34169A (es) ?compuestos heterociclicos microbiocidas,composiciones que los contienen, y métodos para controlar o prevenir la infestación de plantas
DOP2016000007A (es) Pirazolpiridinas sustituidas
CL2017000244A1 (es) Formulaciones de compuestos biológicos para instilación intravesical.
CL2015003787A1 (es) Compuestos para la formación de pro-drogas
FR3008822B1 (fr) Creation d'isotopes par faisceaux laser
MX2016015106A (es) Derivados de dipicolilamina y sus usos farmaceuticos.
MX2018015965A (es) Composicion de dos componentes.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
UY35690A (es) Composiciones farmacéuticas de ranolazina y dronedarona
BR112015020076A2 (pt) composição agroquímica suspensa aquosa
CL2015001920A1 (es) Formulaciones de lorazepam de liberación sostenida